Juan Andres - Jul 16, 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Technical Operations and Quality Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Jul 16, 2021
Transactions value $
-$5,404,350
Form type
4
Date filed
7/20/2021, 04:15 PM
Previous filing
Jul 16, 2021
Next filing
Jul 23, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $61.1K +5K $12.21* 5K Jul 16, 2021 Direct F1
transaction MRNA Common Stock Sale -$1.38M -5K -100% $276.51 0 Jul 16, 2021 Direct F1
transaction MRNA Common Stock Options Exercise $61.1K +5K $12.21* 5K Jul 19, 2021 Direct F1
transaction MRNA Common Stock Options Exercise $122K +10K +200% $12.21* 15K Jul 19, 2021 Direct F1
transaction MRNA Common Stock Sale -$4.27M -15K -100% $284.40 0 Jul 19, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -1.12% $0.00 440K Jul 16, 2021 Common Stock 5K $12.21 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -1.14% $0.00 435K Jul 19, 2021 Common Stock 5K $12.21 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -10K -2.3% $0.00 425K Jul 19, 2021 Common Stock 10K $12.21 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021.
F2 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.

Remarks:

Chief Technical Operations and Quality Officer